Salvatore Annunziata*, Riccardo Laudicella, Federico Caobelli, Daniele A. Pizzuto and Young Aimn Working Group Pages 6 - 13 ( 8 )
Background: 18F-FDG PET/CT has been suggested as an effective tool to stage patients affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of hybrid PET/ceCT has emerged.
Objective: To review recent evidence on the role of PET/CT in melanoma staging as well as its potential for future developments.
Methods: A comprehensive computer literature search of PubMed/MEDLINE was carried out to find relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.
Results: Some recent studies about potentials and limitations of 18F-FDG PET/CT in staging melanoma, new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed and discussed.
Conclusion: PET/CT plays an important role in the staging workup of patients affected by melanoma. New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in this field.
PET-CT, CT, PET, 18F-FDG, melanoma, contrast.
Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina ME, Department of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Department of Nuclear Medicine, University Hospital Zurich/University of Zurich, Raemistrasse 100, 8091 Zurich, Executive Committee of the Italian Association of Nuclear Medicine, Milan